Company intelligence / Profile preview
Reveal Pharmaceuticals
Cambridge, Massachusetts, United Statesrevealpharma.com ↗
- Ownership
- Private
- Development stage
- Preclinical
01
Overview
Reveal Pharmaceuticals has developed RVP‑001, a manganese-based general-purpose MRI contrast agent designed to replace gadolinium-based agents and avoid heavy metal accumulation risks. The company’s pipeline also includes first-in-class fibrogenesis imaging agents for diagnosing and monitoring active fibrotic disease. RVP‑001 is currently advancing through clinical trials.
- Therapeutic areas
- OtherHematologyCardiovascular
- Modalities
- Small molecule (manganese-based MRI contrast agent)Imaging agent (fibrogenesis imaging agents)
- Industry
- Biotech
02
Drug pipeline
1 asset03
Partnerships
No major pharmaceutical or biotech partnerships publicly disclosed as of June 2025.
Beyond the preview
Go deeper on Reveal Pharmaceuticals.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Reveal Pharmaceuticals.